Non-targeted metabolomics detection was conducted to identify alterations in the metabolites of MASLD patients.<h4>Results</h4>MASLD patients showed significantly elevated levels of XOR activity, and this increase was positively correlated with significantly altered markers of oxidative stress and inflammatory factors, including increased malondialdehyde levels, tumor necrosis factor-α and interleukin-6. This evidence concerns the gene XDH and metabolic dysfunction-associated steatotic liver disease.